Stockscreener 앱 받기
15.60
0.58%
0.09
시간 외 거래:
15.70
0.10
+0.64%
전일 마감가:
$15.51
열려 있는:
$15.73
하루 거래량:
2.16M
Relative Volume:
0.85
시가총액:
$12.10B
수익:
$220.00K
순이익/손실:
$-1.08B
주가수익비율:
-10.80
EPS:
-1.4448
순현금흐름:
$-326.53M
1주 성능:
-3.55%
1개월 성능:
-3.05%
6개월 성능:
-18.54%
1년 성능:
-21.01%
1일 변동 폭
$15.47
$16.21
1주일 범위
$15.25
$16.34
52주 변동 폭
$13.83
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
15.60 | 12.03B | 220.00K | -1.08B | -326.53M | -1.4448 |
VRTX
Vertex Pharmaceuticals Inc
|
451.24 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
736.53 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
681.85 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
306.66 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
143.98 | 29.32B | 606.42M | -1.28B | -997.58M | -6.403 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-17 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-17 | 개시 | Barclays | Underweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Neutral |
| 2025-07-01 | 개시 | UBS | Buy |
| 2025-06-11 | 개시 | Leerink Partners | Underperform |
| 2025-03-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | Goldman | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Responsive Playbooks and the SMMT Inflection - Stock Traders Daily
Trade Recap: Does Summit Therapeutics Inc have a sustainable dividend2026 Investor Takeaways & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT) - The Globe and Mail
SMMT PE Ratio & Valuation, Is SMMT Overvalued - Intellectia AI
Summit Therapeutics Inc. (SMMT) focused on non-small cell lung cancer trial of Ivonescimab - MSN
Summit Therapeutics Inc.Common Stock (NQ: SMMT - FinancialContent
Jefferies downgrades Summit Therapeutics (SMMT) - MSN
Should Jefferies’ Downgrade and Ivonesimab Focus Shape Summit Therapeutics’ (SMMT) Risk‑Reward Profile? - simplywall.st
SMMT Downgraded by Jefferies, Price Target Slashed by 64% | SMMT Stock News - GuruFocus
Summit Therapeutics (NASDAQ:SMMT) Rating Lowered to "Hold" at Jefferies Financial Group - MarketBeat
Summit Therapeutics downgraded to Hold from Buy at Jefferies - TipRanks
SMMT SEC FilingsSummit Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Summit Therapeutics (NASDAQ:SMMT) Trading 6.5% HigherTime to Buy? - MarketBeat
How correlated is Summit Therapeutics Inc to the S P5002026 Chart Watch & Advanced Technical Signal Analysis - baoquankhu1.vn
WINTON GROUP Ltd Makes New Investment in Summit Therapeutics PLC $SMMT - MarketBeat
Understanding the Setup: (SMMT) and Scalable Risk - Stock Traders Daily
Summit Therapeutics at The Citizens Life Sciences Conference: Strategic Insights on Ivonescimab - Investing.com Nigeria
Earnings Report: Is Summit Therapeutics Inc impacted by rising ratesQuarterly Portfolio Review & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Earnings Recap: How correlated is Summit Therapeutics Inc to the S P5002026 Outlook & Reliable Entry Point Alerts - baoquankhu1.vn
Summit Therapeutics’ Earnings Call Highlights OS Hurdles - The Globe and Mail
Summit Therapeutics (NASDAQ:SMMT) Upgraded by Zacks Research to Hold Rating - MarketBeat
Summit Therapeutics (SMMT) ends 2025 with strong cash reserves and increased clinical investment - MSN
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aug Outlook: Can Summit Therapeutics Inc stock outperform in a bear marketDollar Strength & Risk Managed Investment Entry Signals - baoquankhu1.vn
Why Summit Therapeutics (SMMT) Is Down 6.3% After Wider 2025 Loss and ESOP Shelf Filing - simplywall.st
Is Summit Therapeutics (SMMT) Now Pricing In Too Much Hope After Strong Multi Year Gains - simplywall.st
Rafferty Asset Management LLC Purchases 140,323 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Is Summit Therapeutics (SMMT) Pricing Reflect Long Term Value After Recent Share Price Swings - Yahoo Finance
Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment - Finviz
10 Stocks With Explosive Growth Potential - Insider Monkey
Summit Therapeutics at TD Cowen Conference: Strategic Focus on Ivonesimab - Investing.com
SMMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Summit Therapeutics Inc. (SMMT) Stock Analysis: Biotech Innovator with an 89.92% Potential Upside - DirectorsTalk Interviews
Vanguard Group Inc. Purchases 2,706,056 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab - Insider Monkey
The Technical Signals Behind (SMMT) That Institutions Follow - Stock Traders Daily
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Q1 EPS Estimate for Summit Therapeutics Increased by Analyst - MarketBeat
Summit Therapeutics to Present at Upcoming Investor Conferences - Business Wire
How Summit’s Deeper 2025 Loss and Ivonescimab’s FDA Path At Summit Therapeutics (SMMT) Has Changed Its Investment Story - simplywall.st
Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright cuts Summit Therapeutics stock price target on China trial timing uncertainty - Investing.com Australia
Summit Therapeutics Shares Slip Following Mixed Results from Lung Cancer Trial - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Summit Therapeutics (SMMT) and Intuitive Surgical (ISRG) - The Globe and Mail
Summit Therapeutics Inc (SMMT) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Summit Therapeutics Inc (SMMT) Q4 2025 Earnings Call Highlights: - GuruFocus
Earnings Call Summary | Summit Therapeutics(SMMT.US) Q4 2025 Earnings Conference - 富途牛牛
SMMT: Analyst Lowers Price Target to $30, Maintains Buy Rating | - GuruFocus
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus - Finviz
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.55%
0.19%
자본화:
|
볼륨(24시간):